Medicilon Co-organizes Shanghai European and American Alumni Association’s Biomedicine Year-end Meeting

jpkrcn

お知らせ

企業動向

あなたはここにいる:ホーム > お知らせ > 企業動向 > The meeting of the B...

The meeting of the Biomedical Branch of the Shanghai European and American Alumni Association

著者:medicilon   アップロード:2019-12-09  閲読回数:

On December 7, 2019, the 2019 annual meeting of the Biomedical Branch of the Shanghai European and American Alumni Association was held in Shanghai Pudong International Talent Hub。 There were more than 120 biomedical entrepreneurs, investors and scientists from hospitals and scientific institutions to join the meeting。 The annual meeting was organized by the Biomedicine Branch of Shanghai European and American Alumni Association。 Shanghai Pudong International Talent Hub and Shanghai Medicilon Inc。 were the co-organizers and sponsors。

The meeting highlights were the matching of enterprises with national strategic plans, the best way to choose the track & respond to the science and technology board and the selection of collaboration and win-win topics in the industry. It has established a comprehensive platform for exchanges, cooperation and academic discussions for biomedical scientists, entrepreneurs and investors in the pharmaceutical industry.

The conference set up an effective platform for scholars, entrepreneurs and investors in the pharmaceutical industry. The participants exchanged enthusiasm during the meeting. The conference promoted exchanges and collaborations between the guests and they gave a lot of valuable recommendations

the 2019 annual meeting of the Biomedical Branch of the Shanghai European and American Alumni Association

The Annual Meeting

Presentation by Guest 1

Presentation by Guest 1

Presentation by Guest 2

Presentation by Guest 2

Round Table Discussion

Round Table Discussion

Presentation by Guest 3

Presentation by Guest 3

About Medicilon

Medicilon (Stock Code: 688202) is a Contract Research Organization (CRO) in Shanghai。 Medicilon has established a collection of services which include compound synthesis, compound screening, structural biology, pharmacodynamic evaluation, pharmacokinetic evaluation, toxicology evaluation, preparation research and new drug registration。 The comprehensive technical service platforms that Medicilon provides comply with international standards and have been recognized by international drug regulatory authorities。 The animal laboratory facilities have obtained AAALAC certification and the National Drug Administration NMPA GLP certificate。 The facilities have also reached the US Food and Drug Administration GLP standards。 Medicilon helps the clients to reach their goals faster in terms of time with efficient and cost-effective professional services。

上の:Medicilon is selected for 2019 Influential Science and Technology Startup Company

下に:Medicilon successfully exhibited in the SAPA CT Annual Conference

多多中彩票平台 亿乐彩平台 608彩票平台 鑫乐博彩票平台 彩客网平台 369彩票平台 易盈彩票平台 五百万彩票平台网 679彩票平台 大福彩票